Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 11 de junho de 2024

Myriad Genetics, Inc.

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriads MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriads MyChoice Tests) is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudia Arabia, Singapore, and United Arab Emirates.

HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer. Myriads MyChoice Tests determine HRD status in women with ovarian cancer. Clinicians can order this test through their local pathology labs and samples are sent to Myriad Genetics.

This collaboration delivers on both companies shared commitment to improve care for patients with advanced ovarian cancer by facilitating access to genetic testing and demonstrates a mutual dedication to meeting an unmet need for patients who otherwise may not have access to testing.

Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalized ovarian cancer treatment decisions, said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics. In the pursuit of advancing healthcare equity, Myriad is committed to extending the reach of our diagnostic solutions, like Myriads MyChoice Tests into additional markets to support more targeted patient care based on their genomic profile.

About Myriads MyChoice Test
Myriads MyChoice® test is the most comprehensive tumor test for determining HRD status based on the assessment of genomic alterations in genes such as BRCA1 and BRCA2 and Genomic Instability Score (GIS) status using Myriads proprietary algorithm.  It enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to treatment with targeted therapies.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com. 

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including that this collaboration will increase access to HRD testing and can help clinicians guide more personalized ovarian cancer treatment decisions for patients. These forward-looking statements are managements expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the companys filings with the U.S. Securities and Exchange Commission, including the companys Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the companys Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com

A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire